EXPLORE!

Evolving Landscape of DPP-4 CVOTs: CARMELINA in Focus

  971 Views

Dr Merlin Thomas, Australia    26 November 2018

  1. DPP-4 inhibitors are a good treatment option in type 2 diabetes as they are easy to use, no titration is required, have sustained efficacy across a broad range of settings, are weight neutral; hypoglycemia is rare.
  2. Linagliptin has the broadest clinical evidences among the DPP-4 inhibitors.
  3. The CARMELINA trial reinforces the clinical safety profile of adults with type 2 diabetes.
  4. Linagliptin demonstrated consistent CV safety profile in patients with type 2 diabetes, established ASCVD and/or CKD in the trial.
  5. Also, linagliptin showed no increase in risk of heart failure hospitalization, even in high risk patients including those with renal impairment.
  6. Linagliptin demonstrated a reassuring kidney safety profile with an additional reduction in albuminuria progression. The number of patients who had ≥1 new antidiabetic drug introduced post-baseline was much lower with linagliptin vs. placebo.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.